The telomere/telomerase system in chronic inflammatory diseases. Cause or effect?

Genes

Volumn 7, Issue 9, 2016, Pages

  Kordinas, Vasileios ^a,b   Ioannidis, Anastasios ^b,c   Chatzipanagiotou, Stylianos ^b  

^a Department of Urology   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF PELOPONNESE   (Greece)

Author keywords

Inflammation; Senescence; Telomerase; Telomeres

Indexed keywords

C REACTIVE PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; OXIDIZED LOW DENSITY LIPOPROTEIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR NECROSIS FACTOR;

ALCOHOLISM; ALZHEIMER DISEASE; ANXIETY DISORDER; ATHEROSCLEROSIS; BIPOLAR DISORDER; CARCINOGENESIS; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC PERIODONTITIS; CLAUDICATION; CYTOMEGALOVIRUS INFECTION; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; EMPHYSEMA; ENZYME ACTIVITY; EPSTEIN BARR VIRUS INFECTION; FIBROSING ALVEOLITIS; HEART FAILURE; HEART INFARCTION; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIFESTYLE; LISTERIOSIS; MULTIPLE SCLEROSIS; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAPILLOMAVIRUS INFECTION; PARKINSON DISEASE; PATHOGENESIS; POSTTRAUMATIC STRESS DISORDER; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TELOMERE LENGTH; ULCERATIVE COLITIS;

EID: 84989361058     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes7090060     Document Type: Review

References (212)

1. Kaminker, P.G.; Kim, S.H.; Desprez, P.Y.; Campisi, J. A novel form of the telomere-associated protein TIN2 localizes to the nuclear matrix. Cell Cycle 2009, 8, 931–939.
2. Garavis, M.; Gonzalez, C.; Villasante, A. On the origin of the eukaryotic chromosome: The role of noncanonical DNA structures in telomere evolution. Genome Biol. Evol. 2013, 5, 1142–1150.
3. Wood, A.M.; Laster, K.; Rice, E.L.; Kosak, S.T. A beginning of the end: New insights into the functional organization of telomeres. Nucleus 2015, 6, 172–178.
4. Cusanelli, E.; Chartrand, P. Telomeric noncoding RNA: Telomeric repeat-containing RNA in telomere biology. Wiley Interdiscip. Rev. RNA 2014, 5, 407–419.
5. Tumpel, S.; Rudolph, K.L. The role of telomere shortening in somatic stem cells and tissue aging: Lessons from telomerase model systems. Ann. N. Y. Acad. Sci. 2012, 1266, 28–39.
6. Barnes, P.J. Mechanisms of development of multimorbidity in the elderly. Eur. Respir. J. 2015, 4, 790–806.
7. Fyhrquist, F.; Tiitu, A.; Saijonmaa, O.; Forsblom, C.; Groop, P.H.; FinnDiane, S.G. Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. J. Intern. Med. 2010, 267, 278–286.
8. Rubin, H. The disparity between human cell senescence in vitro and lifelong replication in vivo. Nat. Biotechnol. 2002, 20, 675–681.
9. Kong, C.M.; Lee, X.W.; Wang, X. Telomere shortening in human diseases. FEBS J. 2013, 280, 3180–3193.
10. Webb, C.J.; Zakian, V.A. Telomerase RNA is more than a DNA template. RNA Biol. 2016, 13, 1–7.
11. Sandin, S.; Rhodes, D. Telomerase structure. Curr. Opin. Struct. Biol. 2014, 25, 104–110.
12. Smogorzewska, A.; de Lange, T. Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 2004, 73, 177–208.
13. Podlevsky, J.D.; Chen, J.J. It all comes together at the ends: Telomerase structure, function, and biogenesis. Mutat. Res. 2012, 730, 3–11.
14. Gomez, D.L.; Farina, H.G.; Gomez, D.E. Telomerase regulation: A key to inhibition? Int. J. Oncol. 2013, 43, 1351–1356.
15. Simons, M.J. Questioning causal involvement of telomeres in aging. Ageing Res. Rev. 2015, 24, 191–196.
16. Greider, C.W. Telomeres and senescence: The history, the experiment, the future. Curr. Biol. 1998, 8, R178–R181.
17. Cong, Y.S.; Wright, W.E.; Shay, J.W. Human telomerase and its regulation. Microbiol. Mol. Biol. Rev. 2002, 66, 407–425.
18. Wyatt, H.D.; West, S.C.; Beattie, T.L. InTERTpreting telomerase structure and function. Nucleic Acids Res. 2010, 38, 5609–5622.
19. Wu, X.Q.; Huang, C.; He, X.; Tian, Y.Y.; Zhou, D.X.; He, Y.; Liu, X.H.; Li, J. Feedback regulation of telomerase reverse transcriptase: New insight into the evolving field of telomerase in cancer. Cell Signal 2013, 25, 2462–2468.
20. Zhang, J.; Rane, G.; Dai, X.; Shanmugam, M.K.; Arfuso, F.; Samy, R.P.; Lai, M.K.; Kappei, D.; Kumar, A.P.; Sethi, G. Ageing and the telomere connection: An intimate relationship with inflammation. Ageing Res. Rev. 2016, 25, 55–69.
21. Marques-Rocha, J.L.; Samblas, M.; Milagro, F.I.; Bressan, J.; Martinez, J.A.; Marti, A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 2015, 29, 3595–3611.
22. Minihane, A.M.; Vinoy, S.; Russell, W.R.; Baka, A.; Roche, H.M.; Tuohy, K.M.; Teeling, J.L.; Blaak, E.E.; Fenech, M.; Vauzour, D., et al. Low-grade inflammation, diet composition and health: Current research evidence and its translation. Br. J. Nutr. 2015, 114, 999–1012.
23. Kaulmann, A.; Bohn, T. Carotenoids, inflammation, and oxidative stress—Implications of cellular signaling pathways and relation to chronic disease prevention. Nutr. Res. 2014, 34, 907–929.
24. Osnes, L.T.; Nakken, B.; Bodolay, E.; Szodoray, P. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies—Novel tool for diagnostics and patient follow-up. Autoimmun Rev. 2013, 12, 967–971.
25. Panickar, K.S.; Jewell, D.E. The beneficial role of anti-inflammatory dietary ingredients in attenuating markers of chronic low-grade inflammation in aging. Horm. Mol. Biol. Clin. Investig. 2015, 23, 59–70.
26. Bootz, F.; Neri, D. Immunocytokines: A novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov. Today 2016, 21, 180–189.
27. Hohensinner, P.J.; Goronzy, J.J.; Weyand, C.M. Telomere dysfunction, autoimmunity and aging. Aging Dis. 2011, 2, 524–537.
28. Zhu, H.; Belcher, M.; van der Harst, P. Healthy aging and disease: Role for telomere biology? Clin. Sci. 2011, 120, 427–440.
29. Effros, R.B. Kleemeier Award Lecture 2008—the canary in the coal mine: Telomeres and human healthspan. J. Gerontol. A Biol. Sci. Med. Sci. 2009, 64, 511–515.
30. Riera, C.E.; Merkwirth, C.; De Magalhaes Filho, C.D.; Dillin, A. Signaling Networks Determining Life Span. Annu. Rev. Biochem. 2016, 85, 35–64.
31. Zhang, F.; Cheng, D.; Wang, S.; Zhu, J. Human Specific Regulation of the Telomerase Reverse Transcriptase Gene. Genes 2016.
32. Bar, C.; Blasco, M.A. Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases. F1000Research 2016.
33. Manabe, I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ. J. 2011, 75, 2739–2748.
34. Lawrence, T.; Gilroy, D.W. Chronic inflammation: A failure of resolution? Int. J. Exp. Pathol. 2007, 88, 85–94.
35. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009.
36. Serhan, C.N.; Krishnamoorthy, S.; Recchiuti, A.; Chiang, N. Novel anti-inflammatory—Pro-resolving mediators and their receptors. Curr. Top. Med. Chem. 2011, 11, 629–647.
37. Nathan, C.; Ding, A. Nonresolving inflammation. Cell 2010, 140, 871–882.
38. Futosi, K.; Fodor, S.; Mocsai, A. Neutrophil cell surface receptors and their intracellular signal transduction pathways. Int. Immunopharmacol. 2013, 17, 638–650.
39. Narayanan, K.B.; Park, H.H. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis 2015, 20, 196–209.
40. Liu, Q.; Ding, J.L. The molecular mechanisms of TLR-signaling cooperation in cytokine regulation. Immunol. Cell Biol. 2016, 94, 538–542.
41. Lee, N.K.; Lee, S.Y. Modulation of life and death by the tumor necrosis factor receptor-associated factors (TRAFs). J. Biochem. Mol. Biol. 2002, 35, 61–66.
42. Gasparini, C.; Feldmann, M. NF-kappaB as a target for modulating inflammatory responses. Curr. Pharm. Des. 2012, 18, 5735–5745.
43. Iyer, S.S.; Cheng, G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev. Immunol. 2012, 32, 23–63.
44. Kozicky, L.K.; Sly, L.M. Phosphatase regulation of macrophage activation. Semin Immunol 2015, 27, 276–285.
45. Tokunaga, F. Linear ubiquitination-mediated NF-kappaB regulation and its related disorders. J. Biochem. 2013, 154, 313–323.
46. Yang, X.D.; Sun, S.C. Targeting signaling factors for degradation, an emerging mechanism for TRAF functions. Immunol. Rev. 2015, 266, 56–71.
47. Franceschi, C.; Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69, S4–S9.
48. Wagner, K.H.; Cameron-Smith, D.; Wessner, B.; Franzke, B. Biomarkers of Aging: From Function to Molecular Biology. Nutrients 2016.
49. Toussaint, O.; Royer, V.; Salmon, M.; Remacle, J. Stress-induced premature senescence and tissue ageing. Biochem. Pharmacol. 2002, 64, 1007–1009.
50. Sikora, E.; Arendt, T.; Bennett, M.; Narita, M. Impact of cellular senescence signature on ageing research. Ageing Res. Rev. 2011, 10, 146–152.
51. Childs, B.G.; Durik, M.; Baker, D.J.; van Deursen, J.M. Cellular senescence in aging and age-related disease: From mechanisms to therapy. Nat. Med. 2015, 21, 1424–1435.
52. Sikora, E.; Bielak-Zmijewska, A.; Mosieniak, G. Cellular senescence in ageing, age-related disease and longevity. Curr. Vasc. Pharmacol. 2014, 12, 698–706.
53. Effros, R.B. Telomere/telomerase dynamics within the human immune system: Effect of chronic infection and stress. Exp. Gerontol. 2011, 46, 135–140.
54. Andrews, N.P.; Fujii, H.; Goronzy, J.J.; Weyand, C.M. Telomeres and immunological diseases of aging. Gerontology 2010, 56, 390–403.
55. Velarde, M.C.; Demaria, M.; Campisi, J. Senescent cells and their secretory phenotype as targets for cancer therapy. Interdiscip. Top Gerontol. 2013, 38, 17–27.
56. Salminen, A.; Kauppinen, A.; Kaarniranta, K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012, 24, 835–845.
57. Ovadya, Y.; Krizhanovsky, V. Senescent cells: SASPected drivers of age-related pathologies. Biogerontology 2014, 15, 627–642.
58. Lasry, A.; Ben-Neriah, Y. Senescence-associated inflammatory responses: Aging and cancer perspectives. Trends Immunol. 2015, 36, 217–228.
59. Zhu, Y.; Armstrong, J.L.; Tchkonia, T.; Kirkland, J.L. Cellular senescence and the senescent secretory phenotype in age-related chronic diseases. Curr. Opin. Clin. Nutr. Metab. Care 2014, 17, 324–328.
60. Aravinthan, A. Cellular senescence: A hitchhiker’s guide. Hum. Cell 2015, 28, 51–64.
61. Jurk, D.; Wilson, C.; Passos, J.F.; Oakley, F.; Correia-Melo, C.; Greaves, L.; Saretzki, G.; Fox, C.; Lawless, C.; Anderson, R., et al. Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nat. Commun. 2014.
62. Ghosh, A.S.; Tergaonkar, V. Telomeres and inflammation: Rap1 joins the ends? Cell Cycle 2010, 9, 3834–3835.
63. Correia-Melo, C.; Hewitt, G.; Passos, J.F. Telomeres, oxidative stress and inflammatory factors: Partners in cellular senescence? Longev. Healthspan. 2014.
64. Rai, P. Oxidation in the nucleotide pool, the DNA damage response and cellular senescence: Defective bricks build a defective house. Mutat. Res. 2010, 703, 71–81.
65. Sarkar, D.; Fisher, P.B. Molecular mechanisms of aging-associated inflammation. Cancer Lett. 2006, 236, 13–23.
66. Fumagalli, M.; Rossiello, F.; Clerici, M.; Barozzi, S.; Cittaro, D.; Kaplunov, J.M.; Bucci, G.; Dobreva, M.; Matti, V.; Beausejour, C.M., et al. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat. Cell Biol. 2012, 14, 355–365.
67. Hewitt, G.; Jurk, D.; Marques, F.D.; Correia-Melo, C.; Hardy, T.; Gackowska, A.; Anderson, R.; Taschuk, M.; Mann, J.; Passos, J.F. Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat. Commun. 2012.
68. Friedrich, U.; Griese, E.; Schwab, M.; Fritz, P.; Thon, K.; Klotz, U. Telomere length in different tissues of elderly patients. Mech. Ageing Dev. 2000, 119, 89–99.
69. Bozinovski, S.; Anthony, D.; Vlahos, R. Targeting pro-resolution pathways to combat chronic inflammation in COPD. J. Thorac. Dis. 2014, 6, 1548–1556.
70. Wilson, M.S.; Wynn, T.A. Pulmonary fibrosis: Pathogenesis, etiology and regulation. Mucosal Immunol. 2009, 2, 103–121.
71. Mroz, R.M.; Noparlik, J.; Chyczewska, E.; Braszko, J.J.; Holownia, A. Molecular basis of chronic inflammation in lung diseases: New therapeutic approach. J. Physiol. Pharmacol. 2007, 58, 453–460.
72. Barnes, P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016, 138, 16–27.
73. Gansner, J.M.; Rosas, I.O. Telomeres in lung disease. Transl. Res. 2013, 162, 343–352.
74. Albrecht, E.; Sillanpaa, E.; Karrasch, S.; Alves, A.C.; Codd, V.; Hovatta, I.; Buxton, J.L.; Nelson, C.P.; Broer, L.; Hagg, S., et al. Telomere length in circulating leukocytes is associated with lung function and disease. Eur. Respir. J. 2014, 43, 983–992.
75. Adnot, S.; Amsellem, V.; Boyer, L.; Marcos, E.; Saker, M.; Houssaini, A.; Kebe, K.; Dagouassat, M.; Lipskaia, L.; Boczkowski, J. Telomere dysfunction and cell senescence in chronic lung diseases: Therapeutic potential. Pharmacol. Ther. 2015, 153, 125–134.
76. Bozkus, F.; Guler, S.; Simsek, S. Serum telomerase levels and COPD exacerbations. Respir. Care 2016, 61, 359–365.
77. Zhou, F.; Onizawa, S.; Nagai, A.; Aoshiba, K. Epithelial cell senescence impairs repair process and exacerbates inflammation after airway injury. Respir. Res. 2011.
78. Amsellem, V.; Gary-Bobo, G.; Marcos, E.; Maitre, B.; Chaar, V.; Validire, P.; Stern, J.B.; Noureddine, H.; Sapin, E.; Rideau, D., et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011, 184, 1358–1366.
79. Stanley, S.E.; Chen, J.J.; Podlevsky, J.D.; Alder, J.K.; Hansel, N.N.; Mathias, R.A.; Qi, X.; Rafaels, N.M.; Wise, R.A.; Silverman, E.K., et al. Telomerase mutations in smokers with severe emphysema. J. Clin. Investig. 2015, 125, 563–570.
80. Birch, J.; Anderson, R.K.; Correia-Melo, C.; Jurk, D.; Hewitt, G.; Marques, F.M.; Green, N.J.; Moisey, E.; Birrell, M.A.; Belvisi, M.G., et al. DNA damage response at telomeres contributes to lung aging and chronic obstructive pulmonary disease. Am. J. Physiol. Lung Cell Mol. Physiol. 2015, 309, L1124–L1137.
81. Birch, J.; Victorelli, S.; Rahmatika, D.; Anderson, R.K.; Jiwa, K.; Moisey, E.; Ward, C.; Fisher, A.J.; Soyza, A.D.; Passos, J.F. Telomere dysfunction and senescence-associated pathways in bronchiectasis. Am. J. Respir. Crit. Care Med. 2016, 193, 929–932.
82. Povedano, J.M.; Martinez, P.; Flores, J.M.; Mulero, F.; Blasco, M.A. Mice with pulmonary fibrosis driven by telomere dysfunction. Cell Rep. 2015, 12, 286–299.
83. Camelo, A.; Dunmore, R.; Sleeman, M.A.; Clarke, D.L. The epithelium in idiopathic pulmonary fibrosis: Breaking the barrier. Front. Pharmacol. 2014.
84. Jin, H.L.; Dong, J.C. Pathogenesis of idiopathic pulmonary fibrosis: From initial apoptosis of epithelial cells to lung remodeling? Chin. Med. J. 2011, 124, 4330–4338.
85. Le Saux, C.J.; Davy, P.; Brampton, C.; Ahuja, S.S.; Fauce, S.; Shivshankar, P.; Nguyen, H.; Ramaseshan, M.; Tressler, R.; Pirot, Z., et al. A novel telomerase activator suppresses lung damage in a murine model of idiopathic pulmonary fibrosis. PLoS ONE 2013, 8, e58423.
86. Armanios, M. Telomeres and age-related disease: How telomere biology informs clinical paradigms. J. Clin. Investig. 2013, 123, 996–1002.
87. Chen, R.; Zhang, K.; Chen, H.; Zhao, X.; Wang, J.; Li, L.; Cong, Y.; Ju, Z.; Xu, D.; Williams, B.R., et al. Telomerase deficiency causes alveolar stem cell senescence-associated low-grade inflammation in lungs. J. Biol. Chem. 2015, 290, 30813–30829.
88. Lee, J.; Taneja, V.; Vassallo, R. Cigarette smoking and inflammation: Cellular and molecular mechanisms. J. Dent. Res. 2012, 91, 142–149.
89. Verde, Z.; Reinoso-Barbero, L.; Chicharro, L.; Garatachea, N.; Resano, P.; Sanchez-Hernandez, I.; Rodriguez Gonzalez-Moro, J.M.; Bandres, F.; Santiago, C.; Gomez-Gallego, F. Effects of cigarette smoking and nicotine metabolite ratio on leukocyte telomere length. Environ. Res. 2015, 140, 488–494.
90. Muezzinler, A.; Mons, U.; Dieffenbach, A.K.; Butterbach, K.; Saum, K.U.; Schick, M.; Stammer, H.; Boukamp, P.; Holleczek, B.; Stegmaier, C., et al. Smoking habits and leukocyte telomere length dynamics among older adults: Results from the ESTHER cohort. Exp. Gerontol. 2015, 70, 18–25.
91. Yim, H.W.; Slebos, R.J.; Randell, S.H.; Umbach, D.M.; Parsons, A.M.; Rivera, M.P.; Detterbeck, F.C.; Taylor, J.A. Smoking is associated with increased telomerase activity in short-term cultures of human bronchial epithelial cells. Cancer Lett. 2007, 246, 24–33.
92. Brooks-Worrell, B.; Palmer, J.P. Immunology in the Clinic Review Series; focus on metabolic diseases: Development of islet autoimmune disease in type 2 diabetes patients: Potential sequelae of chronic inflammation. Clin. Exp. Immunol. 2012, 167, 40–46.
93. Itariu, B.K.; Stulnig, T.M. Autoimmune aspects of type 2 diabetes mellitus—A mini-review. Gerontology 2014, 60, 189–196.
94. Goldfine, A.B.; Fonseca, V.; Shoelson, S.E. Therapeutic approaches to target inflammation in type 2 diabetes. Clin. Chem. 2011, 57, 162–167.
95. Liew, C.W.; Holman, A.; Kulkarni, R.N. The roles of telomeres and telomerase in beta-cell regeneration. Diabetes Obes. Metab. 2009, 11, 21–29.
96. Qi Nan, W.; Ling, Z.; Bing, C. The influence of the telomere-telomerase system on diabetes mellitus and its vascular complications. Expert Opin. Ther. Targets 2015, 19, 849–864.
97. Tamura, Y.; Takubo, K.; Aida, J.; Araki, A.; Ito, H. Telomere attrition and diabetes mellitus. Geriatr. Gerontol. Int. 2016, 16, 66–74.
98. Kuhlow, D.; Florian, S.; von Figura, G.; Weimer, S.; Schulz, N.; Petzke, K.J.; Zarse, K.; Pfeiffer, A.F.; Rudolph, K.L.; Ristow, M. Telomerase deficiency impairs glucose metabolism and insulin secretion. Aging 2010, 2, 650–658.
99. Mulder, H. Is shortening of telomeres the missing link between aging and the Type 2 Diabetes epidemic? Aging 2010, 2, 634–636.
100. Sun, X.; Han, F.; Yi, J.; Hou, N.; Cao, Z. The effect of telomerase activity on vascular smooth muscle cell proliferation in type 2 diabetes in vivo and in vitro. Mol. Med. Rep. 2013, 7, 1636–1640.
101. Ma, D.; Zhu, W.; Hu, S.; Yu, X.; Yang, Y. Association between oxidative stress and telomere length in Type 1 and Type 2 diabetic patients. J. Endocrinol. Invest. 2013, 36, 1032–1037.
102. Astrup, A.S.; Tarnow, L.; Jorsal, A.; Lajer, M.; Nzietchueng, R.; Benetos, A.; Rossing, P.; Parving, H.H. Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia 2010, 53, 45–48.
103. Zhou, Y.; Ning, Z.; Lee, Y.; Hambly, B.D.; McLachlan, C.S. Shortened leukocyte telomere length in type 2 diabetes mellitus: Genetic polymorphisms in mitochondrial uncoupling proteins and telomeric pathways. Clin. Transl. Med. 2016.
104. Chizzolini, C.; Dayer, J.M.; Miossec, P. Cytokines in chronic rheumatic diseases: Is everything lack of homeostatic balance? Arthritis Res. Ther. 2009.
105. Kunz, M.; Ibrahim, S.M. Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity. Mediators Inflamm. 2009.
106. Santegoets, K.C.; van Bon, L.; van den Berg, W.B.; Wenink, M.H.; Radstake, T.R. Toll-like receptors in rheumatic diseases: Are we paying a high price for our defense against bugs? FEBS Lett. 2011, 585, 3660–3666.
107. Steer, S.E.; Williams, F.M.; Kato, B.; Gardner, J.P.; Norman, P.J.; Hall, M.A.; Kimura, M.; Vaughan, R.; Aviv, A.; Spector, T.D. Reduced telomere length in rheumatoid arthritis is independent of disease activity and duration. Ann. Rheum. Dis. 2007, 66, 476–480.
108. Fujii, H.; Shao, L.; Colmegna, I.; Goronzy, J.J.; Weyand, C.M. Telomerase insufficiency in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 2009, 106, 4360–4365.
109. Colmegna, I.; Diaz-Borjon, A.; Fujii, H.; Schaefer, L.; Goronzy, J.J.; Weyand, C.M. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum. 2008, 58, 990–1000.
110. Dehbi, A.Z.; Radstake, T.R.; Broen, J.C. Accelerated telomere shortening in rheumatic diseases: Cause or consequence? Expert Rev. Clin. Immunol. 2013, 9, 1193–1204.
111. Georgin-Lavialle, S.; Aouba, A.; Mouthon, L.; Londono-Vallejo, J.A.; Lepelletier, Y.; Gabet, A.S.; Hermine, O. The telomere/telomerase system in autoimmune and systemic immune-mediated diseases. Autoimmun. Rev. 2010, 9, 646–651.
112. Fessler, J.; Raicht, A.; Husic, R.; Ficjan, A.; Duftner, C.; Schwinger, W.; Dejaco, C.; Schirmer, M. Premature senescence of T-cell subsets in axial spondyloarthritis. Ann. Rheum. Dis. 2016, 75, 748–754.
113. Montoya-Ortiz, G. Immunosenescence, aging, and systemic lupus erythematous. Autoimmune Dis. 2013.
114. Wu, C.H.; Hsieh, S.C.; Li, K.J.; Lu, M.C.; Yu, C.L. Premature telomere shortening in polymorphonuclear neutrophils from patients with systemic lupus erythematosus is related to the lupus disease activity. Lupus 2007, 16, 265–272.
115. Haque, S.; Rakieh, C.; Marriage, F.; Ho, P.; Gorodkin, R.; Teh, L.S.; Snowden, N.; Day, P.J.; Bruce, I.N. Shortened telomere length in patients with systemic lupus erythematosus. Arthritis Rheum. 2013, 65, 1319–1323.
116. Hoffecker, B.M.; Raffield, L.M.; Kamen, D.L.; Nowling, T.K. Systemic lupus erythematosus and vitamin D deficiency are associated with shorter telomere length among African Americans: A case-control study. PLoS ONE 2013, 8, e63725.
117. Kurosaka, D.; Yasuda, J.; Yoshida, K.; Yoneda, A.; Yasuda, C.; Kingetsu, I.; Toyokawa, Y.; Yokoyama, T.; Saito, S.; Yamada, A. Abnormal telomerase activity and telomere length in T and B cells from patients with systemic lupus erythematosus. J. Rheumatol. 2006, 33, 1102–1107.
118. Kurosaka, D.; Yasuda, J.; Yoshida, K.; Yokoyama, T.; Ozawa, Y.; Obayashi, Y.; Kingetsu, I.; Saito, S.; Yamada, A. Telomerase activity and telomere length of peripheral blood mononuclear cells in SLE patients. Lupus 2003, 12, 591–599.
119. Klapper, W.; Moosig, F.; Sotnikova, A.; Qian, W.; Schroder, J.O.; Parwaresch, R. Telomerase activity in B and T lymphocytes of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 2004, 63, 1681–1683.
120. Zhou, J.G.; Qing, Y.F.; Yang, Q.B.; Xie, W.G.; Zhao, M.C. Changes in the expression of telomere maintenance genes might play a role in the pathogenesis of systemic lupus erythematosus. Lupus 2011, 20, 820–828.
121. Wu, K.; Higashi, N.; Hansen, E.R.; Lund, M.; Bang, K.; Thestrup-Pedersen, K. Telomerase activity is increased and telomere length shortened in T cells from blood of patients with atopic dermatitis and psoriasis. J. Immunol. 2000, 165, 4742–4747.
122. Liu, X.; Lin, J.; Wang, L.; Zhang, Z.; Hou, S.; Yang, G. Telomerase activity in peripheral blood mononuclear cells of psoriatic patients correlates with disease severity. Br. J. Dermatol. 2008, 158, 637–639.
123. Coussens, E.; Grine, L.; Bostoen, J.; Mielants, H.; Lambert, J. Analysis of telomere length as predictive marker in psoriasis for comorbidities. Exp. Dermatol. 2016, 25, 388–390.
124. Guan, J.Z.; Guan, W.P.; Maeda, T.; Guoqing, X.; GuangZhi, W.; Makino, N. Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening. Mol. Cell Biochem. 2015, 400, 183–187.
125. Tamayo, M.; Mosquera, A.; Rego, J.I.; Fernandez-Sueiro, J.L.; Blanco, F.J.; Fernandez, J.L. Differing patterns of peripheral blood leukocyte telomere length in rheumatologic diseases. Mutat. Res. 2010, 683, 68–73.
126. Silverstein, D.M. Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr. Nephrol. 2009, 24, 1445–1452.
127. Akchurin, O.M.; Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif. 2015, 39, 84–92.
128. Miyamoto, T.; Carrero, J.J.; Stenvinkel, P. Inflammation as a risk factor and target for therapy in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2011, 20, 662–668.
129. Imig, J.D.; Ryan, M.J. Immune and inflammatory role in renal disease. Compr. Physiol. 2013, 3, 957–976.
130. Kordinas, V.; Tsirpanlis, G.; Nicolaou, C.; Zoga, M.; Ioannidis, A.; Ioannidou, V.; Bersimis, S.; Petrihou, C.; Savva, L.; Legakis, N.J., et al. Is there a connection between inflammation, telomerase activity and the transcriptional status of telomerase reverse transcriptase in renal failure? Cell Mol. Biol. Lett. 2015, 20, 222–236.
131. Tsirpanlis, G.; Chatzipanagiotou, S.; Boufidou, F.; Kordinas, V.; Alevyzaki, F.; Zoga, M.; Kyritsis, I.; Stamatelou, K.; Triantafyllis, G.; Nicolaou, C. Telomerase activity is decreased in peripheral blood mononuclear cells of hemodialysis patients. Am. J. Nephrol. 2006, 26, 91–96.
132. Wills, L.P.; Schnellmann, R.G. Telomeres and telomerase in renal health. J. Am. Soc. Nephrol. 2011, 22, 39–41.
133. Raschenberger, J.; Kollerits, B.; Titze, S.; Kottgen, A.; Barthlein, B.; Ekici, A.B.; Forer, L.; Schonherr, S.; Weissensteiner, H.; Haun, M., et al. Do telomeres have a higher plasticity than thought? Results from the German Chronic Kidney Disease (GCKD) study as a high-risk population. Exp. Gerontol. 2015, 72, 162–166.
134. Stefanidis, I.; Voliotis, G.; Papanikolaou, V.; Chronopoulou, I.; Eleftheriadis, T.; Kowald, A.; Zintzaras, E.; Tsezou, A. Telomere Length in Peripheral Blood Mononuclear Cells of Patients on Chronic Hemodialysis Is RelatedWith Telomerase Activity and Treatment Duration. Artif. Organs. 2015, 39, 756–764.
135. Raschenberger, J.; Kollerits, B.; Ritchie, J.; Lane, B.; Kalra, P.A.; Ritz, E.; Kronenberg, F. Association of relative telomere length with progression of chronic kidney disease in two cohorts: Effect modification by smoking and diabetes. Sci. Rep. 2015.
136. Westhoff, J.H.; Schildhorn, C.; Jacobi, C.; Homme, M.; Hartner, A.; Braun, H.; Kryzer, C.; Wang, C.; von Zglinicki, T.; Kranzlin, B.; Gretz, N.; Melk, A. Telomere shortening reduces regenerative capacity after acute kidney injury. J. Am. Soc. Nephrol. 2010, 21, 327–336.
137. De Vusser, K.; Pieters, N.; Janssen, B.; Lerut, E.; Kuypers, D.; Jochmans, I.; Monbaliu, D.; Pirenne, J.; Nawrot, T.; Naesens, M. Telomere length, cardiovascular risk and arteriosclerosis in human kidneys: An observational cohort study. Aging 2015, 7, 766–775.
138. Robinson, J.G.; Leon, A.S. The prevention of cardiovascular disease. Emphasis on secondary prevention. Med. Clin. North. Am. 1994, 78, 69–98.
139. Ketelhuth, D.F.; Hansson, G.K. Modulation of autoimmunity and atherosclerosis—Common targets and promising translational approaches against disease. Circ. J. 2015, 79, 924–933.
140. Frostegard, J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013.
141. Matsuura, E.; Atzeni, F.; Sarzi-Puttini, P.; Turiel, M.; Lopez, L.R.; Nurmohamed, M.T. Is atherosclerosis an autoimmune disease? BMC Med. 2014.
142. Castellon, X.; Bogdanova, V. Chronic Inflammatory Diseases and Endothelial Dysfunction. Aging Dis. 2016, 7, 81–89.
143. Hofmann, U.; Frantz, S. How can we cure a heart “in flame”? A translational view on inflammation in heart failure. Basic Res. Cardiol. 2013.
144. Serrano, A.L.; Andres, V. Telomeres and cardiovascular disease: Does size matter? Circ. Res. 2004, 94, 575–584.
145. Voghel, G.; Thorin-Trescases, N.; Farhat, N.; Nguyen, A.; Villeneuve, L.; Mamarbachi, A.M.; Fortier, A.; Perrault, L.P.; Carrier, M.; Thorin, E. Cellular senescence in endothelial cells from atherosclerotic patients is accelerated by oxidative stress associated with cardiovascular risk factors. Mech. Ageing Dev. 2007, 128, 662–671.
146. Fuster, J.J.; Andres, V. Telomere biology and cardiovascular disease. Circ. Res. 2006, 99, 1167–1180.
147. Bekaert, S.; de Meyer, T.; Rietzschel, E.R.; de Buyzere, M.L.; de Bacquer, D.; Langlois, M.; Segers, P.; Cooman, L.; Van Damme, P.; Cassiman, P., et al. Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell 2007, 6, 639–647.
148. Gizard, F.; Heywood, E.B.; Findeisen, H.M.; Zhao, Y.; Jones, K.L.; Cudejko, C.; Post, G.R.; Staels, B.; Bruemmer, D. Telomerase activation in atherosclerosis and induction of telomerase reverse transcriptase expression by inflammatory stimuli in macrophages. Arterioscler Thromb. Vasc. Biol. 2011, 31, 245–252.
149. Calvert, P.A.; Liew, T.V.; Gorenne, I.; Clarke, M.; Costopoulos, C.; Obaid, D.R.; O’Sullivan, M.; Shapiro, L.M.; McNab, D.C.; Densem, C.G., et al. Leukocyte telomere length is associated with high-risk plaques on virtual histology intravascular ultrasound and increased proinflammatory activity. Arterioscler Thromb. Vasc. Biol. 2011, 31, 2157–2164.
150. Slavich, G.M.; Irwin, M.R. From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. Psychol. Bull. 2014, 140, 774–815.
151. Lindqvist, D.; Epel, E.S.; Mellon, S.H.; Penninx, B.W.; Revesz, D.; Verhoeven, J.E.; Reus, V.I.; Lin, J.; Mahan, L.; Hough, C.M., et al. Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging. Neurosci. Biobehav. Rev. 2015, 55, 333–364.
152. Muneer, A. Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers. Psychiatry Investig. 2016, 13, 18–33.
153. Muller, N.; Weidinger, E.; Leitner, B.; Schwarz, M.J. The role of inflammation in schizophrenia. Front. Neurosci. 2015.
154. Hughes, M.M.; Connor, T.J.; Harkin, A. Stress-related immune markers in depression: Implications for treatment. Int. J. Neuropsychopharmacol. 2016.
155. Verhoeven, J.E.; Revesz, D.; Epel, E.S.; Lin, J.; Wolkowitz, O.M.; Penninx, B.W. Major depressive disorder and accelerated cellular aging: Results from a large psychiatric cohort study. Mol. Psychiatry 2014, 19, 895–901.
156. Deng, W.; Cheung, S.T.; Tsao, S.W.; Wang, X.M.; Tiwari, A.F. Telomerase activity and its association with psychological stress, mental disorders, lifestyle factors and interventions: A systematic review. Psychoneuroendocrinology 2016, 64, 150–163.
157. Wolkowitz, O.M.; Mellon, S.H.; Epel, E.S.; Lin, J.; Dhabhar, F.S.; Su, Y.; Reus, V.I.; Rosser, R.; Burke, H.M.; Kupferman, E., et al. Leukocyte telomere length in major depression: Correlations with chronicity, inflammation and oxidative stress–preliminary findings. PLoS ONE 2011, 6, e17837.
158. Kiecolt-Glaser, J.K.; Gouin, J.P.; Weng, N.P.; Malarkey, W.B.; Beversdorf, D.Q.; Glaser, R. Childhood adversity heightens the impact of later-life caregiving stress on telomere length and inflammation. Psychosom. Med. 2011, 73, 16–22.
159. Boccardi, V.; Pelini, L.; Ercolani, S.; Ruggiero, C.; Mecocci, P. From cellular senescence to Alzheimer’s disease: The role of telomere shortening. Ageing Res. Rev. 2015, 22, 1–8.
160. Lukens, J.N.; Van Deerlin, V.; Clark, C.M.; Xie, S.X.; Johnson, F.B. Comparisons of telomere lengths in peripheral blood and cerebellum in Alzheimer’s disease. Alzheimers Dement. 2009, 5, 463–469.
161. Spilsbury, A.; Miwa, S.; Attems, J.; Saretzki, G. The role of telomerase protein TERT in Alzheimer’s disease and in tau-related pathology in vitro. J. Neurosci. 2015, 35, 1659–1674.
162. Gonzalez-Giraldo, Y.; Forero, D.A.; Echeverria, V.; Gonzalez, J.; Avila-Rodriguez, M.; Garcia-Segura, L.M.; Barreto, G.E. Neuroprotective effects of the catalytic subunit of telomerase: A potential therapeutic target in the central nervous system. Ageing Res. Rev. 2016, 28, 37–45.
163. Eerola, J.; Kananen, L.; Manninen, K.; Hellstrom, O.; Tienari, P.J.; Hovatta, I. No evidence for shorter leukocyte telomere length in Parkinson’s disease patients. J. Gerontol. A Biol. Sci. Med. Sci. 2010, 65, 1181–1184.
164. Eitan, E.; Hutchison, E.R.; Mattson, M.P. Telomere shortening in neurological disorders: An abundance of unanswered questions. Trends Neurosci. 2014, 37, 256–263.
165. Forero, D.A.; Gonzalez-Giraldo, Y.; Lopez-Quintero, C.; Castro-Vega, L.J.; Barreto, G.E.; Perry, G. Telomere length in Parkinson’s disease: A meta-analysis. Exp. Gerontol. 2016, 75, 53–55.
166. Schurks, M.; Buring, J.; Dushkes, R.; Gaziano, J.M.; Zee, R.Y.; Kurth, T. Telomere length and Parkinson’s disease in men: A nested case-control study. Eur. J. Neurol. 2014, 21, 93–99.
167. Watfa, G.; Dragonas, C.; Brosche, T.; Dittrich, R.; Sieber, C.C.; Alecu, C.; Benetos, A.; Nzietchueng, R. Study of telomere length and different markers of oxidative stress in patients with Parkinson’s disease. J. Nutr. Health Aging 2011, 15, 277–281.
168. Franzese, O.; Adamo, R.; Pollicita, M.; Comandini, A.; Laudisi, A.; Perno, C.F.; Aquaro, S.; Bonmassar, E. Telomerase activity, hTERT expression, and phosphorylation are downregulated in CD4 (+) T lymphocytes infected with human immunodeficiency virus type 1 (HIV-1). J. Med. Virol. 2007, 79, 639–646.
169. Chou, J.P.; Ramirez, C.M.; Wu, J.E.; Effros, R.B. Accelerated aging in HIV/AIDS: Novel biomarkers of senescent human CD8+ T cells. PLoS ONE 2013, 8, e64702.
170. Fitzpatrick, M.E.; Singh, V.; Bertolet, M.; Lucht, L.; Kessinger, C.; Michel, J.; Logar, A.; Weinman, R.; McMahon, D.; Norris, K.A., et al. Relationships of pulmonary function, inflammation, and T-cell activation and senescence in an HIV-infected cohort. AIDS 2014, 28, 2505–2515.
171. Williams, K.; Seiss, K.; Beamon, J.; Pereyra, F.; Rosenberg, E.S.; Walker, B.D.; Yu, X.G.; Lichterfeld, M. Epigenetic regulation of telomerase expression in HIV-1-specific CD8+ T cells. AIDS 2010, 24, 1964–1966.
172. Torres, R.A.; Lewis, W. Aging and HIV/AIDS: Pathogenetic role of therapeutic side effects. Lab. Investig. 2014, 94, 120–128.
173. Cote, H.C.; Soudeyns, H.; Thorne, A.; Alimenti, A.; Lamarre, V.; Maan, E.J.; Sattha, B.; Singer, J.; Lapointe, N.; Money, D.M., et al. Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: Shorter telomeres with uncontrolled HIV viremia. PLoS ONE 2012, 7, e39266.
174. Lichterfeld, M.; Mou, D.; Cung, T.D.; Williams, K.L.; Waring, M.T.; Huang, J.; Pereyra, F.; Trocha, A.; Freeman, G.J.; Rosenberg, E.S., et al. Telomerase activity of HIV-1-specific CD8+ T cells: Constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 2008, 112, 3679–3687.
175. Reynoso, R.; Laufer, N.; Bolcic, F.; Quarleri, J. Telomerase activity in peripheral blood mononuclear cells from HIV and HIV-HCV coinfected patients. Virus Res. 2010, 147, 284–287.
176. Bollmann, F.M. Telomerase inhibition may contribute to accelerated mitochondrial aging induced by anti-retroviral HIV treatment. Med. Hypotheses 2013, 81, 285–287.
177. Leeansyah, E.; Cameron, P.U.; Solomon, A.; Tennakoon, S.; Velayudham, P.; Gouillou, M.; Spelman, T.; Hearps, A.; Fairley, C.; Smit de, V., et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos (t) ide reverse transcriptase inhibitors: A potential factor contributing to HIV-associated accelerated aging. J. Infect. Dis. 2013, 207, 1157–1165.
178. Fan, X.G.; Huang, Y.; Tang, F.Q.; Yi, H. Telomerase activity of peripheral blood lymphocytes in patients with chronic hepatitis B. Immunol. Lett. 2000, 73, 7–11.
179. Biron-Shental, T.; Amiel, A.; Anchidin, R.; Sharony, R.; Hadary, R.; Kitay-Cohen, Y. Telomere length and telomerase reverse transcriptase mRNA expression in patients with hepatitis C. Hepatogastroenterology 2013, 60, 1713–1716.
180. Dowd, J.B.; Bosch, J.A.; Steptoe, A.; Blackburn, E.H.; Lin, J.; Rees-Clayton, E.; Aiello, A.E. Cytomegalovirus is associated with reduced telomerase activity in the Whitehall II cohort. Exp. Gerontol. 2013, 48, 385–390.
181. Samba-Louaka, A.; Stavru, F.; Cossart, P. Role for telomerase in Listeria monocytogenes infection. Infect. Immun. 2012, 80, 4257–4263.
182. Bellon, M.; Nicot, C. Regulation of telomerase and telomeres: Human tumor viruses take control. J. Natl. Cancer Inst. 2008, 100, 98–108.
183. Daubenmier, J.; Lin, J.; Blackburn, E.; Hecht, F.M.; Kristeller, J.; Maninger, N.; Kuwata, M.; Bacchetti, P.; Havel, P.J.; Epel, E. Changes in stress, eating, and metabolic factors are related to changes in telomerase activity in a randomized mindfulness intervention pilot study. Psychoneuroendocrinology 2012, 37, 917–928.
184. Shalev, I.; Entringer, S.; Wadhwa, P.D.; Wolkowitz, O.M.; Puterman, E.; Lin, J.; Epel, E.S. Stress and telomere biology: A lifespan perspective. Psychoneuroendocrinology 2013, 38, 1835–1842.
185. Crous-Bou, M.; Fung, T.T.; Prescott, J.; Julin, B.; Du, M.; Sun, Q.; Rexrode, K.M.; Hu, F.B.; de Vivo, I. Mediterranean diet and telomere length in Nurses’ Health Study: Population based cohort study. BMJ 2014.
186. Boccardi, V.; Esposito, A.; Rizzo, M.R.; Marfella, R.; Barbieri, M.; Paolisso, G. Mediterranean diet, telomere maintenance and health status among elderly. PLoS ONE 2013, 8, e62781.
187. Carulli, L.; Anzivino, C.; Baldelli, E.; Zenobii, M.F.; Rocchi, M.B.; Bertolotti, M. Telomere length elongation after weight loss intervention in obese adults. Mol. Genet. Metab. 2016, 118, 138–142.
188. Pavanello, S.; Hoxha, M.; Dioni, L.; Bertazzi, P.A.; Snenghi, R.; Nalesso, A.; Ferrara, S.D.; Montisci, M.; Baccarelli, A. Shortened telomeres in individuals with abuse in alcohol consumption. Int. J. Cancer 2011, 129, 983–992.
189. Aida, J.; Yokoyama, A.; Izumiyama, N.; Nakamura, K.; Ishikawa, N.; Poon, S.S.; Fujiwara, M.; Sawabe, M.; Matsuura, M.; Arai, T., et al. Alcoholics show reduced telomere length in the oesophagus. J. Pathol. 2011, 223, 410–416.
190. Gonzalez-Reimers, E.; Santolaria-Fernandez, F.; Martin-Gonzalez, M.C.; Fernandez-Rodriguez, C.M.; Quintero-Platt, G. Alcoholism: A systemic proinflammatory condition. World J. Gastroenterol. 2014, 20, 14660–14671.
191. Invernizzi, P.; Bernuzzi, F.; Lleo, A.; Pozzoli, V.; Bignotto, M.; Zermiani, P.; Crosignani, A.; Battezzati, P.M.; Zuin, M.; Podda, M., et al. Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Dig. Liver Dis. 2014, 46, 363–368.
192. Risques, R.A.; Lai, L.A.; Brentnall, T.A.; Li, L.; Feng, Z.; Gallaher, J.; Mandelson, M.T.; Potter, J.D.; Bronner, M.P.; Rabinovitch, P.S. Ulcerative colitis is a disease of accelerated colon aging: Evidence from telomere attrition and DNA damage. Gastroenterology 2008, 135, 410–418.
193. Steffens, J.P.; Masi, S.; D’Aiuto, F.; Spolidorio, L.C. Telomere length and its relationship with chronic diseases—New perspectives for periodontal research. Arch. Oral. Biol. 2013, 58, 111–117.
194. Morosetti, R.; Broccolini, A.; Sancricca, C.; Gliubizzi, C.; Gidaro, T.; Tonali, P.A.; Ricci, E.; Mirabella, M. Increased aging in primary muscle cultures of sporadic inclusion-body myositis. Neurobiol. Aging 2010, 31, 1205–1214.
195. Djojosubroto, M.W.; Choi, Y.S.; Lee, H.W.; Rudolph, K.L. Telomeres and telomerase in aging, regeneration and cancer. Mol. Cells 2003, 15, 164–175.
196. Arai, Y.; Martin-Ruiz, C.M.; Takayama, M.; Abe, Y.; Takebayashi, T.; Koyasu, S.; Suematsu, M.; Hirose, N.; von Zglinicki, T. Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians. EBioMedicine 2015, 2, 1549–1558.
197. Cattaneo, D.; Remuzzi, G. Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. J. Ren. Nutr. 2005, 15, 71–76.
198. Deans, K.A.; Sattar, N. “Anti-inflammatory” drugs and their effects on type 2 diabetes. Diabetes Technol. Ther. 2006, 8, 18–27.
199. Boccardi, V.; Barbieri, M.; Rizzo, M.R.; Marfella, R.; Esposito, A.; Marano, L.; Paolisso, G. A new pleiotropic effect of statins in elderly: Modulation of telomerase activity. FASEB J. 2013, 27, 3879–3885.
200. Donnini, S.; Terzuoli, E.; Ziche, M.; Morbidelli, L. Sulfhydryl angiotensin-converting enzyme inhibitor promotes endothelial cell survival through nitric-oxide synthase, fibroblast growth factor-2, and telomerase cross-talk. J. Pharmacol. Exp. Ther. 2010, 332, 776–784.
201. Beavers, K.M.; Brinkley, T.E.; Nicklas, B.J. Effect of exercise training on chronic inflammation. Clin. Chim. Acta 2010, 411, 785–793.
202. Tousoulis, D.; Psarros, C.; Demosthenous, M.; Patel, R.; Antoniades, C.; Stefanadis, C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J. Am. Coll. Cardiol. 2014, 63, 2491–2502.
203. Machowska, A.; Carrero, J.J.; Lindholm, B.; Stenvinkel, P. Therapeutics targeting persistent inflammation in chronic kidney disease. Transl. Res. 2016, 167, 204–213.
204. Wolkowitz, O.M.; Reus, V.I.; Mellon, S.H. Of sound mind and body: Depression, disease, and accelerated aging. Dialogues Clin. Neurosci. 2011, 13, 25–39.
205. Sallam, N.; Laher, I. Exercise modulates oxidative stress and inflammation in aging and cardiovascular diseases. Oxid. Med. Cell Longev. 2016.
206. Das, U.N. Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules. Lipids. Health Dis. 2008.
207. Khalsa, D.S. Stress, meditation, and Alzheimer’s disease prevention: Where the evidence stands. J. Alzheimers Dis. 2015, 48, 1–12.
208. Yen, Y.C.; Lung, F.W. Older adults with higher income or marriage have longer telomeres. Age Ageing 2013, 42, 234–239.
209. Sprouse, A.A.; Steding, C.E.; Herbert, B.S. Pharmaceutical regulation of telomerase and its clinical potential. J. Cell Mol. Med. 2012, 16, 1–7.
210. Molgora, B.; Bateman, R.; Sweeney, G.; Finger, D.; Dimler, T.; Effros, R.B.; Valenzuela, H.F. Functional assessment of pharmacological telomerase activators in human T cells. Cells 2013, 2, 57–66.
211. Ip, F.C.; Ng, Y.P.; An, H.J.; Dai, Y.; Pang, H.H.; Hu, Y.Q.; Chin, A.C.; Harley, C.B.; Wong, Y.H.; Ip, N.Y. Cycloastragenol is a potent telomerase activator in neuronal cells: Implications for depression management. Neurosignals 2014, 22, 52–63.
212. Townsley, D.M.; Dumitriu, B.; Liu, D.; Biancotto, A.; Weinstein, B.; Chen, C.; Hardy, N.; Mihalek, A.D.; Lingala, S.; Kim, Y.J., et al. Danazol Treatment for Telomere Diseases. N. Engl. J. Med. 2016, 374, 1922–1931.